https://www.healthwiresyria.com/article/910517765-alpha-tau-announces-upcoming-podium-presentation-at-the-ahns-12th-international-conference-on-head-and-neck-cancer-showcasing-study-results-of-alpha Health Wire Syria en PressRelease 2026-05-05T13:14:32+00:00 Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.healthwiresyria.com/article/910516832-sk-pharmteco-achieves-sbti-validation-for-2040-net-zero-science-based-targets Health Wire Syria en PressRelease 2026-05-05T13:03:00+00:00 SK pharmteco Achieves SBTi Validation for 2040 Net-Zero Science-Based Targets https://ml.globenewswire.com/media/038236c2-8cb0-4ff3-8b7e-cbb02b768b37/small/sk-pharmteco-3-png.png https://www.healthwiresyria.com/article/910516701-chemed-corporation-to-present-at-the-bank-of-america-securities-health-care-conference-2026 Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026 https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://www.healthwiresyria.com/article/910516733-karl-jacob-s-fix-your-insulin-hits-1-amazon-best-seller-in-diabetes-category-launches-limited-time-0-99-reader-promotion Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 Karl Jacob's "Fix Your Insulin" Hits #1 Amazon Best Seller in Diabetes Category, Launches Limited-Time $0.99 Reader Promotion https://pressranger.s3.us-west-1.amazonaws.com/3242430/The-Insulin-Fix_Cover-6.jpg https://www.healthwiresyria.com/article/910516841-heartsciences-signs-first-saas-revenues-agreement-following-full-launch-of-myovista-insights Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™ https://ml.globenewswire.com/media/800a6aae-74f3-42bb-9199-5e169ed9b881/small/heartsciences-png.png https://www.healthwiresyria.com/article/910517024-precision-optics-announces-receipt-of-3-5-million-follow-on-production-order-for-single-use-ophthalmic-program Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 Precision Optics Announces Receipt of $3.5 Million Follow-On Production Order for Single-Use Ophthalmic Program https://ml.globenewswire.com/media/6d86ce33-7e41-41e5-90b0-1c74cd89785e/small/precision-optics-logo-jpg.jpg https://www.healthwiresyria.com/article/910517058-bicycle-health-expands-leadership-team-to-increase-access-to-evidence-based-opioid-use-disorder-care Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 Bicycle Health Expands Leadership Team to Increase Access to Evidence-Based Opioid Use Disorder Care https://ml.globenewswire.com/media/ba03cedc-3d11-4aa5-b226-cb5784309493/small/copy-of-bhvirtualcarelogo-black-2x-jpg.jpg https://www.healthwiresyria.com/article/910517073-maps-state-of-colorado-partner-to-deliver-free-harm-reduction-training-for-first-responders Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 MAPS & State of Colorado Partner to Deliver Free Harm Reduction Training for First Responders https://ml.globenewswire.com/media/4f774750-4742-4818-be22-116e2b2085b1/small/maps-logo-2021-primary-horizontal-white-background-1200x486.jpg https://www.healthwiresyria.com/article/910517086-femasys-enables-ob-gyns-to-deliver-first-line-fertility-treatment-with-initial-commercial-use-of-femaseed-complete Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete https://ml.globenewswire.com/media/c668c3db-ff7f-4eb5-b51a-b8db25e838b4/small/femasys-logo-2-jpg.jpg https://www.healthwiresyria.com/article/910517333-health-canada-authorizes-north-america-s-first-hepatitis-b-rapid-test-biolytical-s-istatis-hepatitis-b-surface-antigen-test Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 Health Canada Authorizes North America’s First Hepatitis B Rapid Test, bioLytical’s iStatis Hepatitis B Surface Antigen Test https://ml.globenewswire.com/media/8c4f4c4f-8565-4ee5-9842-ca4d0dcf67fb/medium/istatis-hepatitis-b-surface-antigen-test.jpg https://www.healthwiresyria.com/article/910517373-biosphere-awarded-9-million-u-s-army-contract-to-develop-on-demand-nutrition-production-system-for-warfighters Health Wire Syria en PressRelease 2026-05-05T13:00:00+00:00 Biosphere Awarded $9 Million U.S. Army Contract to Develop On-Demand Nutrition Production System for Warfighters https://ml.globenewswire.com/media/e816f42d-d6f4-462f-a3af-65eb8d733841/small/logo1-png.png https://www.healthwiresyria.com/article/910516816-cellution-biologics-celebrates-expansion-of-u-s-headquarters-in-roswell-georgia Health Wire Syria en PressRelease 2026-05-05T12:55:00+00:00 Cellution Biologics Celebrates Expansion of U.S. Headquarters in Roswell, Georgia https://ml.globenewswire.com/media/25f5b530-a1f5-4314-a4b9-9d2a0ec2a934/small/cb-logo-colorfs-png.png https://www.healthwiresyria.com/article/910517494-clearmind-medicine-announces-filing-of-european-patent-application-for-novel-psychedelic-compounds-for-the-treatment-of-ptsd Health Wire Syria en PressRelease 2026-05-05T12:50:00+00:00 Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.healthwiresyria.com/article/910517538-clene-announces-7-million-underwritten-offering-of-common-stock Health Wire Syria en PressRelease 2026-05-05T12:45:00+00:00 Clene Announces $7 Million Underwritten Offering of Common Stock https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://www.healthwiresyria.com/article/910507674-ocugen-provides-business-update-with-first-quarter-2026-financial-results Health Wire Syria en PressRelease 2026-05-05T12:32:54+00:00 Ocugen Provides Business Update with First Quarter 2026 Financial Results https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.healthwiresyria.com/article/910506917-sab-bio-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-may-12-2026-08-30-am-et Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET https://ml.globenewswire.com/media/6d99a771-f2c9-4d05-bf57-4f6c070df032/small/sabprimarylogocolorrgb900px72ppi-png.png https://www.healthwiresyria.com/article/910507058-ss-innovations-surpasses-10-500-surgeries-performed-with-the-ssi-mantra-surgical-robotic-system Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 SS Innovations Surpasses 10,500 Surgeries Performed with the SSi Mantra Surgical Robotic System https://ml.globenewswire.com/media/cef267e0-040f-4889-a706-cc4d0ae49e55/small/new-logo-april-23-2025-png.png https://www.healthwiresyria.com/article/910507118-achieve-life-sciences-to-announce-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-12-2026 Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 https://ml.globenewswire.com/media/1026e030-275c-4391-8f9a-65c5c1ec7b88/small/achieve-logo-717x800px-2-1-jpg.jpg https://www.healthwiresyria.com/article/910507145-sofwave-medical-reports-first-quarter-fiscal-2026-financial-results-and-business-highlights Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 Sofwave Medical Reports First Quarter Fiscal 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/9fbd88c7-2eaf-45c3-b046-2d055fe94a07/small/download-png.png https://www.healthwiresyria.com/article/910507153-disc-medicine-reports-first-quarter-2026-financial-results-and-provides-business-update Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/d212c899-9a87-4500-9382-573dfe9f12af/small/disc-logo-horiz-fullcolor-rgb-jpg.jpg https://www.healthwiresyria.com/article/910507252-palisade-bio-reports-additional-phase-1a-b-data-demonstrating-colon-targeted-exposure-and-sustained-ic90-coverage-supporting-once-daily-dosing-in Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis https://ml.globenewswire.com/media/0beaede8-1c7c-4f77-84a7-b1efd54c343c/small/logo-png.png https://www.healthwiresyria.com/article/910507258-cormedix-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-14-2026 Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg https://www.healthwiresyria.com/article/910507278-fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://www.healthwiresyria.com/article/910507452-oragenics-activates-second-site-in-phase-iia-clinical-trial-of-onp-002-for-concussion-and-mild-traumatic-brain-injury Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. https://ml.globenewswire.com/media/8b2c9d06-f009-4a6e-a465-8a1fe9640993/small/logo-jpg.jpg https://www.healthwiresyria.com/article/910507457-profusa-initiates-board-led-process-to-evaluate-strategic-alternatives-and-maximize-shareholder-value Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value https://ml.globenewswire.com/media/a8137a61-b858-48da-9e47-1f1bf8f6ddba/small/profusa-logo-jpg.jpg https://www.healthwiresyria.com/article/910507458-imunon-to-hold-first-quarter-2026-financial-results-and-business-update-conference-call-on-tuesday-may-12-2026 Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026 https://ml.globenewswire.com/media/acf78e45-a45b-456b-93e3-0e39f2122826/small/logo-png.png https://www.healthwiresyria.com/article/910507620-microbot-medical-s-liberty-endovascular-robotic-system-is-now-adopted-by-multiple-accounts-across-key-territories-including-two-access-pvi-pivotal Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.healthwiresyria.com/article/910507662-fibrobiologics-ceo-issues-letter-to-shareholders Health Wire Syria en PressRelease 2026-05-05T12:30:00+00:00 FibroBiologics CEO Issues Letter to Shareholders https://ml.globenewswire.com/media/f3ebedd0-66f2-4e20-b298-4b52bbb42404/medium/pete-o-heeron.jpg https://www.healthwiresyria.com/article/910507657-ocugen-inc-announces-pricing-of-115-million-of-6-75-convertible-senior-notes Health Wire Syria en PressRelease 2026-05-05T12:12:21+00:00 Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.healthwiresyria.com/article/910507636-blood-banking-devices-market-size-to-surpass-usd-9-08-bn-by-2034-driven-by-rising-number-of-blood-banks-globally Health Wire Syria en PressRelease 2026-05-05T12:06:12+00:00 Blood Banking Devices Market Size to Surpass USD 9.08 BN by 2034, Driven by Rising Number of Blood Banks Globally https://ml.globenewswire.com/media/1f4cf0ab-7d76-4136-a6dc-a5545f80f538/small/zion-market-research-jpg.jpg https://www.healthwiresyria.com/article/910507192-noom-names-power-of-habit-author-charles-duhigg-as-advisor-releases-new-research-linking-glp-1-success-to-habit-formation Health Wire Syria en PressRelease 2026-05-05T12:02:00+00:00 Noom Names “Power of Habit” Author Charles Duhigg as Advisor, Releases New Research Linking GLP-1 Success to Habit Formation https://ml.globenewswire.com/media/6b8c0d7a-2154-4867-82d3-f7e88a9793ee/medium/noom-psychosocial-report-findings.jpg https://www.healthwiresyria.com/article/910506877-allarity-therapeutics-advances-stenoparib-toward-pivotal-development-with-phase-3-manufacturing-campaign Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign https://ml-eu.globenewswire.com/media/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544/small/allarity-full-color-rgb-2023jun07-png.png https://www.healthwiresyria.com/article/910506884-spyre-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.healthwiresyria.com/article/910506912-nu-tek-biosciences-presents-data-driven-approach-to-animal-cell-culture-optimization-at-esact-2026 Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences Presents Data-Driven Approach to Animal Cell Culture Optimization at ESACT 2026 https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.healthwiresyria.com/article/910506922-nu-tek-biosciences-pr-sentiert-auf-der-esact-2026-einen-datengest-tzten-ansatz-zur-optimierung-der-tierischen-zellkultur Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences präsentiert auf der ESACT 2026 einen datengestützten Ansatz zur Optimierung der tierischen Zellkultur https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.healthwiresyria.com/article/910506928-nu-tek-biosciences-pr-sente-une-approche-fond-e-sur-les-donn-es-pour-l-optimisation-de-la-culture-de-cellules-animales-lors-de-l-esact-2026 Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences présente une approche fondée sur les données pour l’optimisation de la culture de cellules animales lors de l’ESACT 2026 https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.healthwiresyria.com/article/910506939-healthverity-to-acquire-symphony-health-uniting-clinical-data-and-commercial-analytics-to-accelerate-breakthroughs-across-the-healthcare-ecosystem Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem https://ml.globenewswire.com/media/e2010eff-0993-44c1-a40d-9f0237268a35/medium/healthverity.jpg https://www.healthwiresyria.com/article/910506952-septerna-to-present-at-bank-of-america-securities-health-care-conference Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Septerna to Present at Bank of America Securities Health Care Conference https://ml.globenewswire.com/media/8c635733-2794-456f-9bc4-3b53908acba9/small/septernalogo-black-10x-jpg.jpg https://www.healthwiresyria.com/article/910507011-transplants-org-launches-as-centralized-education-and-navigation-platform-for-organ-and-stem-cell-transplant-patients Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Transplants.org Launches as Centralized Education and Navigation Platform for Organ and Stem Cell Transplant Patients https://ml.globenewswire.com/media/1d980326-1679-4adb-bd02-7e4358b841ce/small/transplants-org-logo-color-jpg.jpg https://www.healthwiresyria.com/article/910507047-clene-to-present-at-upcoming-may-conferences Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Clene to Present at Upcoming May Conferences https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://www.healthwiresyria.com/article/910507089-geron-plans-to-present-at-upcoming-investor-conferences Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Geron Plans to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://www.healthwiresyria.com/article/910507095-minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates https://ml.globenewswire.com/media/69e604cb-25b6-4235-ae9a-17c25cc158b9/small/minerva-logo.jpg https://www.healthwiresyria.com/article/910507163-cg-oncology-to-present-at-upcoming-investor-conferences-in-may Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 CG Oncology to Present at Upcoming Investor Conferences in May https://ml.globenewswire.com/media/9e1cbdea-928e-4ea4-b4cd-33cdc36c6b2f/small/cgoncology-cover-jpg.jpg https://www.healthwiresyria.com/article/910507196-corbus-pharmaceuticals-to-host-in-person-and-virtual-kol-event-at-asco-2026 Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.healthwiresyria.com/article/910507205-zentalis-pharmaceuticals-announces-first-patient-dosed-in-aspenova-phase-3-trial-of-azenosertib-in-patients-with-cyclin-e1-positive-platinum-resistant Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer https://ml.globenewswire.com/media/1b481d6d-51c9-44f0-b33f-81feb1061d2e/small/zentalis-logo-png.png https://www.healthwiresyria.com/article/910507214-picard-medical-announces-pricing-of-5-million-offering Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Picard Medical Announces Pricing of $5 Million Offering https://ml.globenewswire.com/media/93c733bb-b54a-41af-856b-6d01c1f724a2/small/syncardia-x-picard-email-signature-2025-1-png.png https://www.healthwiresyria.com/article/910507244-filana-therapeutics-presents-tsc-related-epilepsy-program-at-eilat-xviii Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII https://ml.globenewswire.com/media/984a6554-2b2a-4cf7-9a32-72ac808d52ac/small/filana400-png.png https://www.healthwiresyria.com/article/910507247-madrigal-adds-clinical-stage-sirna-asset-targeting-pnpla3-to-its-mash-pipeline Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline https://ml.globenewswire.com/media/8fec8de1-1a2e-4f6c-a679-fc43002276ba/small/madrigal-logo-jpg.jpg https://www.healthwiresyria.com/article/910507268-pathai-and-a-c-camargo-cancer-center-announce-cooperation-to-expand-digital-pathology-with-ai-in-brazil-via-sus Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 PathAI and A.C.Camargo Cancer Center Announce Cooperation to Expand Digital Pathology with AI in Brazil via SUS https://ml.globenewswire.com/media/ab2bfc12-ae80-47c6-9345-a98783489ed7/small/pathai-logo-standard-png.png https://www.healthwiresyria.com/article/910507406-cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2026-financial-results Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results https://ml.globenewswire.com/media/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e/small/cogent-biosciences-logo-rgb-png.png https://www.healthwiresyria.com/article/910507408-verrica-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-12-2026 Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 https://ml.globenewswire.com/media/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b/small/verrica-logo-jpg.jpg https://www.healthwiresyria.com/article/910507428-bionano-announces-a-56-increase-in-publications-describing-the-utility-of-ogm-in-rare-diseases-in-q1-2026-vs-q1-2025 Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025 https://ml.globenewswire.com/media/5ba4072e-6e59-46e7-847c-6aaf7755bbbf/small/bionano-rgb-png.png https://www.healthwiresyria.com/article/910507624-mineralys-therapeutics-to-participate-in-the-bank-of-america-securities-health-care-conference Health Wire Syria en PressRelease 2026-05-05T12:00:00+00:00 Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference https://ml.globenewswire.com/media/2f3e6873-8e64-406e-832e-7df0f6d79a56/small/mineralys-therapeutics-logo-jpg.jpg https://www.healthwiresyria.com/article/910507632-latest-digestive-health-supplements-market-size-expected-to-reach-usd-25-86-billion-by-2034-with-6-10-cagr-driven-by-rising-geriatric-population Health Wire Syria en PressRelease 2026-05-05T11:59:13+00:00 [Latest] Digestive Health Supplements Market Size Expected to Reach USD 25.86 Billion by 2034 With 6.10% CAGR, Driven by Rising Geriatric Population Worldwide and Increasing Prevalence of Digestive Health Concerns https://ml.globenewswire.com/media/1f4cf0ab-7d76-4136-a6dc-a5545f80f538/small/zion-market-research-jpg.jpg https://www.healthwiresyria.com/article/910507208-neuronetics-reports-first-quarter-2026-financial-and-operating-results Health Wire Syria en PressRelease 2026-05-05T11:50:00+00:00 Neuronetics Reports First Quarter 2026 Financial and Operating Results https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.healthwiresyria.com/article/910497076-discure-technologies-appoints-dr-ray-baker-to-its-board-of-directors Health Wire Syria en PressRelease 2026-05-05T11:35:00+00:00 Discure Technologies Appoints Dr. Ray Baker to its Board of Directors https://ml.globenewswire.com/media/eb02cf21-747a-4619-8cb2-b3929c46ae7e/small/descure-technologies-logo-png.PNG https://www.healthwiresyria.com/article/910497087-kura-oncology-to-report-first-quarter-2026-financial-results Health Wire Syria en PressRelease 2026-05-05T11:30:00+00:00 Kura Oncology to Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png https://www.healthwiresyria.com/article/910497096-intellia-therapeutics-to-participate-in-upcoming-investor-conferences Health Wire Syria en PressRelease 2026-05-05T11:30:00+00:00 Intellia Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.healthwiresyria.com/article/910497121-compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-corporate-update Health Wire Syria en PressRelease 2026-05-05T11:30:00+00:00 Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update  https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.healthwiresyria.com/article/910497160-bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece Health Wire Syria en PressRelease 2026-05-05T11:30:00+00:00 BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE https://ml.globenewswire.com/media/2074ba9b-0e5b-41fa-baac-553f1345bb75/small/bridge-bio-black-png.png https://www.healthwiresyria.com/article/910497222-surgery-partners-inc-announces-first-quarter-2026-results-reaffirms-full-year-2026-guidance Health Wire Syria en PressRelease 2026-05-05T11:30:00+00:00 Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance https://ml.globenewswire.com/media/d0188456-e6d3-48f9-8479-b40422f00e4c/small/surgerypartnerslinear-1-jpg.jpg https://www.healthwiresyria.com/article/910497278-tris-pharma-appoints-jim-potenziano-ph-d-as-chief-science-and-development-officer Health Wire Syria en PressRelease 2026-05-05T11:30:00+00:00 Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer https://ml.globenewswire.com/media/2ab6667c-5742-4090-afb8-459cd811c92e/small/logo-png.png https://www.healthwiresyria.com/article/910497407-cytokinetics-announces-positive-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive Health Wire Syria en PressRelease 2026-05-05T11:30:00+00:00 Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy https://ml.globenewswire.com/media/adcf634e-a2a7-4cdf-98b3-ca658eab1b35/medium/figure-1-assessments-of-kccq-and-pvo2.png https://www.healthwiresyria.com/article/910497479-nuvectis-pharma-inc-reports-first-quarter-2026-financial-results-and-business-highlights Health Wire Syria en PressRelease 2026-05-05T11:30:00+00:00 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png https://www.healthwiresyria.com/article/910497039-what-to-look-for-in-a-deodorant-in-canada-in-2026 Health Wire Syria en PressRelease 2026-05-05T11:12:15+00:00 What to Look for in a Deodorant in Canada in 2026 https://ml-eu.globenewswire.com/media/MmU2ZTI3ZDAtOWNkMi00Y2Y4LWE5N2EtZWFiZTg0NGFjZTk0LTEzMjI4ODctMjAyNi0wNS0wNS1lbg==/tiny/Beiersdorf-Canada-Inc-.png https://www.healthwiresyria.com/article/910497392-cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of Health Wire Syria en PressRelease 2026-05-05T11:10:00+00:00 Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.healthwiresyria.com/article/910497403-uniqure-announces-first-quarter-2026-financial-results-and-provides-recent-company-updates Health Wire Syria en PressRelease 2026-05-05T11:05:00+00:00 uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates https://ml.globenewswire.com/media/2ba61fe2-12e5-4a01-afe1-419652b31512/small/logo-uniqure-ms-word-orange-jpg.jpg https://www.healthwiresyria.com/article/910497470-sotera-health-delivers-strong-first-quarter-2026-results-and-reaffirms-2026-outlook Health Wire Syria en PressRelease 2026-05-05T11:03:49+00:00 Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook https://ml.globenewswire.com/media/a0ec722c-ad65-4f05-a8ae-bc1aa6cc4db4/small/sotera-png.png https://www.healthwiresyria.com/article/910497148-invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Wire Syria en PressRelease 2026-05-05T11:01:00+00:00 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png https://www.healthwiresyria.com/article/910497078-biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://www.healthwiresyria.com/article/910497083-dupixent-dupilumab-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-eoe-phase-4-trial Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.healthwiresyria.com/article/910497093-kymera-therapeutics-presents-new-preclinical-ibd-data-for-kt-579-a-first-in-class-oral-irf5-degrader-at-digestive-disease-week Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.healthwiresyria.com/article/910497116-orvida-pharma-to-present-functional-endpoint-development-data-in-rare-palmoplantar-skin-disorders-at-the-83rd-annual-meeting-of-the-society-for Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Orvida Pharma to Present Functional Endpoint Development Data in Rare Palmoplantar Skin Disorders at the 83rd Annual Meeting of the Society for Investigative Dermatology and the 2026 Epidermal Differentiation Disorders Symposium https://ml.globenewswire.com/media/cd4d7fc1-6bca-4b1d-a6b3-2314ed21fb79/small/orvida-final-46-jpg.jpg https://www.healthwiresyria.com/article/910497194-editas-medicine-announces-first-quarter-2026-results-and-business-updates Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Editas Medicine Announces First Quarter 2026 Results and Business Updates https://ml.globenewswire.com/media/03686b66-5cbc-40b5-9dfa-be0e7858ac97/small/editas-logo-small-1-jpg.jpg https://www.healthwiresyria.com/article/910497200-climb-bio-hosts-budoprutug-r-d-spotlight-event-highlighting-topline-subcutaneous-formulation-data-broad-b-cell-mediated-disease-opportunity-and Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts https://ml.globenewswire.com/media/2a42b557-6e44-4818-bfce-2238a05f2c43/small/climb-400x400-002-jpg.jpg https://www.healthwiresyria.com/article/910497206-arvinas-to-report-first-quarter-2026-financial-results-on-may-12-2026 Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/563780a0-f8d9-4e37-8665-b622ef2caa5b/small/arvinas-logoart-lg-jpg.jpg https://www.healthwiresyria.com/article/910497213-sotera-health-announces-leadership-transition Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Sotera Health Announces Leadership Transition https://ml.globenewswire.com/media/a0ec722c-ad65-4f05-a8ae-bc1aa6cc4db4/small/sotera-png.png https://www.healthwiresyria.com/article/910497215-relmada-therapeutics-to-present-ndv-01-abstracts-at-aua2026 Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 https://ml.globenewswire.com/media/8a986b0a-11c8-4551-b0ad-ec20fe2fe40a/small/relmada-logo-png.png https://www.healthwiresyria.com/article/910497218-fractyl-health-to-report-first-quarter-2026-financial-results-and-provide-business-updates-on-may-12-2026-and-will-participate-in-an-upcoming Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference https://ml.globenewswire.com/media/3a379315-9c07-4655-883e-7e7f26c67778/small/fractyl-logo-png.png https://www.healthwiresyria.com/article/910497220-electra-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-ipsoprubart-ela026-in-t-cell-malignancies Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies https://ml.globenewswire.com/media/5c28c3ad-0aec-4979-b6c4-12f1d4bf4c46/small/electra-logo-rgb-png.png https://www.healthwiresyria.com/article/910497226-brewdog-announces-partnership-with-underbelly-as-official-beer-supplier-of-underbelly-at-the-edinburgh-fringe Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 BrewDog Announces Partnership with Underbelly as Official Beer Supplier of Underbelly at the Edinburgh Fringe https://ml.globenewswire.com/media/dc1f57dc-8a83-444e-8722-08f858c451af/medium/brewdog-underbelly.jpeg https://www.healthwiresyria.com/article/910497233-axsome-therapeutics-to-participate-in-upcoming-investor-conferences Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Axsome Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/1186f248-bfb6-4258-a391-f2ffd94c5d76/small/axsome-r-morpheus-logo-pos-rgb-png.png https://www.healthwiresyria.com/article/910497236-repligen-reports-first-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg https://www.healthwiresyria.com/article/910497247-atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026 Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 https://ml.globenewswire.com/media/1506ab30-7618-4ed0-98de-e3815adb3aa6/small/avir-png.png https://www.healthwiresyria.com/article/910497290-seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.healthwiresyria.com/article/910497311-eupraxia-pharmaceuticals-reports-erefs-data-from-its-ongoing-phase-1b-2a-resolve-trial-in-eosinophilic-esophagitis-at-digestive-disease-week-ddw Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) https://ml.globenewswire.com/media/0b2bbe4b-1cf9-402e-8ea6-22c0043f310a/small/eupraxia-color-med-res-01-jpg.jpg https://www.healthwiresyria.com/article/910497313-ocular-therapeutix-reports-first-quarter-2026-financial-results-and-business-highlights Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.healthwiresyria.com/article/910497336-rhythm-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-update Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.healthwiresyria.com/article/910497362-nrx-pharmaceuticals-nasdaq-nrxp-announces-initiation-of-commercial-manufacturing-for-preservative-free-ketamine Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.healthwiresyria.com/article/910497386-neuraxis-to-host-first-quarter-2026-results-and-business-update-call-on-tuesday-may-12-2026 Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 https://ml.globenewswire.com/media/a1e3887d-3378-46c5-938d-2b0d5a7c825f/small/neuraxis-logo-png.png https://www.healthwiresyria.com/article/910497398-shopify-delivers-again-as-merchants-clear-100-billion-in-q1-gmv Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Shopify Delivers Again as Merchants Clear $100 Billion in Q1 GMV https://ml.globenewswire.com/media/28cdf29b-fa48-43e3-a710-ea3ab811a26c/small/shopify-logo-black-png.png https://www.healthwiresyria.com/article/910497412-cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million Health Wire Syria en PressRelease 2026-05-05T11:00:00+00:00 Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.healthwiresyria.com/article/910487809-biontech-ver-ffentlicht-ergebnisse-f-r-das-erste-quartal-2026-sowie-informationen-zur-gesch-ftsentwicklung Health Wire Syria en PressRelease 2026-05-05T10:45:00+00:00 BioNTech veröffentlicht Ergebnisse für das erste Quartal 2026 sowie Informationen zur Geschäftsentwicklung https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.healthwiresyria.com/article/910487854-biontech-announces-first-quarter-2026-financial-results-and-corporate-update Health Wire Syria en PressRelease 2026-05-05T10:45:00+00:00 BioNTech Announces First Quarter 2026 Financial Results and Corporate Update https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.healthwiresyria.com/article/910488042-diagonal-therapeutics-expands-executive-leadership-team-appoints-industry-veteran-jonathan-piazza-as-chief-financial-officer Health Wire Syria en PressRelease 2026-05-05T10:30:00+00:00 Diagonal Therapeutics Expands Executive Leadership Team, Appoints Industry Veteran Jonathan Piazza as Chief Financial Officer https://ml.globenewswire.com/media/c2298dfb-0954-43a2-ae2e-866e7a08c7ad/small/diagonallogo-darkcolor-png.png https://www.healthwiresyria.com/article/910487933-new-cda-data-reveals-disconnect-between-knowing-the-risks-of-tanning-and-behaviour-among-gen-z Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 New CDA Data Reveals Disconnect Between Knowing the Risks of Tanning and Behaviour Among Gen Z https://ml.globenewswire.com/media/b78c656b-c304-4227-95af-3944fa238da2/medium/sun-awareness-month-2026.png https://www.healthwiresyria.com/article/910487988-de-nouvelles-donn-es-de-l-acd-r-v-lent-un-d-calage-entre-la-conscience-de-la-g-n-ration-z-des-risques-li-s-au-bronzage-et-ses-habitudes-de-protection Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 De nouvelles données de l’ACD révèlent un décalage entre la conscience de la génération Z des risques liés au bronzage et ses habitudes de protection solaire https://ml.globenewswire.com/media/b78c656b-c304-4227-95af-3944fa238da2/medium/mois-de-mai-le-mois-de-la-prudence-au-soleil-2026.png https://www.healthwiresyria.com/article/910488059-paws-itively-paw-litical-voting-opens-for-4th-annual-cutest-pets-on-parliament-hill Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 Paws-itively Paw-litical: Voting Opens for 4th Annual Cutest Pets on Parliament Hill https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.healthwiresyria.com/article/910488062-poil-itiquement-patte-tant-le-vote-est-ouvert-pour-le-quatri-me-concours-annuel-les-animaux-de-compagnie-les-plus-mignons-sur-la-colline-du Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 Poil-itiquement é-patte-tant : Le vote est ouvert pour le quatrième concours annuel « Les animaux de compagnie les plus mignons sur la Colline du Parlement » https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.healthwiresyria.com/article/910488114-integra-lifesciences-announces-leadership-transition Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 Integra LifeSciences Announces Leadership Transition https://ml.globenewswire.com/media/5adce648-cb01-457f-83ba-c7a1895d1515/medium/stuart-essig-chairman-and-chief-executive-officer.png https://www.healthwiresyria.com/article/910488123-fortrea-reports-first-quarter-2026-results Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 Fortrea Reports First Quarter 2026 Results https://ml.globenewswire.com/media/9fbbe00b-8782-464e-83e6-5843c563884a/small/fortrea-logo-jpg.jpg https://www.healthwiresyria.com/article/910488127-aclarion-announces-second-commercial-agreement-with-weill-cornell-medicine Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.healthwiresyria.com/article/910488131-integra-lifesciences-reports-first-quarter-2026-financial-results Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 Integra LifeSciences Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/80d27f1a-2d8e-44f2-92e9-57e14db38652/small/integra-promotional-logos-integra-logo-full-color-process-1.png https://www.healthwiresyria.com/article/910488144-anteris-technologies-announces-first-u-s-patients-treated-in-global-pivotal-paradigm-trial Health Wire Syria en PressRelease 2026-05-05T10:00:00+00:00 Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial https://ml.globenewswire.com/media/90a5ae8d-7cf0-4a3d-b38c-f4ad7e3fbf0e/small/anteris-tech-rgb-blue-png.png https://www.healthwiresyria.com/article/910458835-latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting Health Wire Syria en PressRelease 2026-05-05T08:00:00+00:00 Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting https://ml-eu.globenewswire.com/media/dc25de9c-07c8-448a-b6af-aea02249e593/medium/global-consensus-on-early-intervention-in-dme.png https://www.healthwiresyria.com/article/910448820-4bio-capital-leads-oversubscribed-61-million-83m-series-a-financing-of-cytospire-therapeutics Health Wire Syria en PressRelease 2026-05-05T07:05:00+00:00 4BIO Capital leads oversubscribed £61 million ($83m) Series A financing of Cytospire Therapeutics  https://ml-eu.globenewswire.com/media/fab6412c-5edc-4903-8a71-51e5ccc6accb/small/4bio-capital-logo-png.png https://www.healthwiresyria.com/article/910448817-cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell Health Wire Syria en PressRelease 2026-05-05T07:00:00+00:00 Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer https://ml-eu.globenewswire.com/media/99e8d7e3-84e7-41a5-84aa-4f03dcb8e2be/medium/natalie-mount.jpg https://www.healthwiresyria.com/article/910448827-neurocare-ag-mdma-tms Health Wire Syria en PressRelease 2026-05-05T07:00:00+00:00 تعلن مجموعة neurocare AG عن ترخيص تسويق الأجهزة الطبية (MDMA) لبيع أجهزة التحفيز المغناطيسي عبر الجمجمة (TMS) في المملكة العربية السعودية https://ml-eu.globenewswire.com/media/d4455b17-37a7-4b42-8dc5-719bbbfe483b/medium/patient-receives-tms-therapy-for-depression-with-neurocare-s.jpg https://www.healthwiresyria.com/article/910448841-neurocare-group-ag-announces-mdma-approval-of-tms-devices-in-saudi-arabia Health Wire Syria en PressRelease 2026-05-05T07:00:00+00:00 neurocare group AG announces MDMA approval of TMS Devices in Saudi Arabia https://ml-eu.globenewswire.com/media/d4455b17-37a7-4b42-8dc5-719bbbfe483b/medium/patient-receives-depression-treatment-using-neurocares-apoll.jpg https://www.healthwiresyria.com/article/910448845-novonesis-delivered-strong-start-to-the-year-with-7-organic-sales-growth-in-q1 Health Wire Syria en PressRelease 2026-05-05T06:18:16+00:00 Novonesis delivered strong start to the year with 7% organic sales growth in Q1 https://ml-eu.globenewswire.com/media/d0c3bcb0-65ab-400f-9219-15fbf4253148/small/novonesis-logo-1-png.png https://www.healthwiresyria.com/article/910439198-abivax-announces-repurchase-of-royalty-certificates-and-pricing-of-45m-38-5m-offering-of-american-depositary-shares Health Wire Syria en PressRelease 2026-05-05T06:00:00+00:00 Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.healthwiresyria.com/article/910429701-santhera-ver-ffentlicht-einladung-zur-ordentlichen-generalversammlung Health Wire Syria en PressRelease 2026-05-05T05:00:00+00:00 Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/ https://www.healthwiresyria.com/article/910429709-santhera-publishes-agenda-for-its-annual-general-meeting Health Wire Syria en PressRelease 2026-05-05T05:00:00+00:00 Santhera Publishes Agenda for its Annual General Meeting https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/logo-jpg.JPG https://www.healthwiresyria.com/article/910410639-axavive-under-investigation-inspecting-the-axon-renewal-anti-aging-benefits-of-the-secret-golden-seed-astragaloside-iv-skin-care-supplement Health Wire Syria en PressRelease 2026-05-05T02:59:01+00:00 Axavive Under Investigation: Inspecting the Axon Renewal Anti-Aging Benefits of the Secret Golden Seed Astragaloside IV Skin Care Supplement https://zingfast.com/wp-content/uploads/2026/05/Axavive-Axon-Renewal.jpg https://www.healthwiresyria.com/article/910400806-gl-control-claims-evaluated-investigating-the-ingredients-benefits-for-blood-sugar-trap-support Health Wire Syria en PressRelease 2026-05-05T02:26:09+00:00 GL Control Claims Evaluated: Investigating the Ingredients Benefits for Blood Sugar Trap Support https://zingfast.com/wp-content/uploads/2026/05/GL-Control-1.jpg https://www.healthwiresyria.com/article/910400749-vital-wrist-monitor-vital-wrist-ball-under-investigation-evaluating-the-brand-claims-product-benefits Health Wire Syria en PressRelease 2026-05-05T01:55:19+00:00 Vital Wrist Monitor & Vital Wrist Ball Under Investigation: Evaluating the Brand Claims & Product Benefits https://zingfast.com/wp-content/uploads/2026/05/Vital-Wrist-Monitor-Vital-Wrist-Ball.jpg https://www.healthwiresyria.com/article/910391392-apa-welcomes-national-focus-on-mental-health-urges-evidence-based-approach-and-continued-focus-on-access-to-care Health Wire Syria en PressRelease 2026-05-05T01:41:48+00:00 APA Welcomes National Focus on Mental Health, Urges Evidence-Based Approach and Continued Focus on Access to Care https://ml.globenewswire.com/media/ODc3ZjcyMWMtNDEyOC00Njc4LWE1MzQtNjQ0YzkzNjhiZDI4LTEyNjc0MTAtMjAyNi0wNS0wNS1lbg==/tiny/American-Psychiatric-Associati.png https://www.healthwiresyria.com/article/910391357-axavive-claims-evaluated-the-golden-seed-switch-for-healthy-skin-support Health Wire Syria en PressRelease 2026-05-05T01:28:26+00:00 Axavive Claims Evaluated: The Golden Seed Switch for Healthy Skin Support https://zingfast.com/wp-content/uploads/2026/05/Axavive.jpg https://www.healthwiresyria.com/article/910371205-pennant-announces-first-quarter-2026-earnings-release-and-call Health Wire Syria en PressRelease 2026-05-04T23:34:37+00:00 Pennant Announces First Quarter 2026 Earnings Release and Call https://ml.globenewswire.com/media/d50f543c-fc54-437d-8007-600644587dfe/small/pennant-logo-png.png https://www.healthwiresyria.com/article/910361255-janell-rae-releases-debut-book-satori-awakening-to-your-truest-self-through-energy-intelligence Health Wire Syria en PressRelease 2026-05-04T22:40:00+00:00 Janell Rae Releases Debut Book Satori: Awakening to Your Truest Self Through Energy Intelligence https://pressranger.s3.us-west-1.amazonaws.com/3225770/Janell-Book-Cover-%288%29.png https://www.healthwiresyria.com/article/910351918-ballad-health-invests-15-million-to-expand-robotic-assisted-surgery-earns-national-accreditation-for-quality-and-surgical-excellence Health Wire Syria en PressRelease 2026-05-04T22:28:36+00:00 Ballad Health invests $15 million to expand robotic-assisted surgery, earns national accreditation for quality and surgical excellence https://ml.globenewswire.com/media/ODk2ZWQ5ZTQtY2ZhZC00YzBmLTkyNDQtNTg2Y2VhYzgxZTkyLTExMzUxNTItMjAyNi0wNS0wNC1lbg==/tiny/Ballad-Health.png https://www.healthwiresyria.com/article/910351879-elite-pro-force-male-enhancement-gummies-claims-evaluated-the-ultra-peak-horse-gelatin-trick-for-men Health Wire Syria en PressRelease 2026-05-04T21:49:17+00:00 Elite Pro Force Male Enhancement Gummies Claims Evaluated: The Ultra Peak Horse Gelatin Trick for Men https://zingfast.com/wp-content/uploads/2026/05/Elite-Pro-Force-Male-Enhancement-Gummies.jpg https://www.healthwiresyria.com/article/910342560-nanobiotix-announces-protocol-amendment-to-ongoing-global-phase-3-head-and-neck-cancer-study Health Wire Syria en PressRelease 2026-05-04T21:29:27+00:00 Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.healthwiresyria.com/article/910342587-nanobiotix-annonce-un-amendement-du-protocole-de-l-tude-mondiale-de-phase-3-sur-le-cancer-de-la-t-te-et-du-cou Health Wire Syria en PressRelease 2026-05-04T21:29:27+00:00 NANOBIOTIX ANNONCE UN AMENDEMENT DU PROTOCOLE DE L’ÉTUDE MONDIALE DE PHASE 3 SUR LE CANCER DE LA TÊTE ET DU COU https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.healthwiresyria.com/article/910342441-jellyfit-claims-evaluated-the-truth-about-jelly-lean-fit-weight-loss-drops-8-ingredients-stacked-with-gelatin-trick-recipe-hack-exposed Health Wire Syria en PressRelease 2026-05-04T21:07:11+00:00 JellyFit Claims Evaluated: The Truth About Jelly Lean Fit Weight Loss Drops' 8 Ingredients Stacked with Gelatin Trick Recipe Hack Exposed https://zingfast.com/wp-content/uploads/2026/05/Jelly-Lean-Fit-Weight-Loss-Drops.jpg https://www.healthwiresyria.com/article/910342340-dentsply-sirona-expands-u-s-distribution-footprint-through-enhanced-agreement-with-atlanta-dental-supply Health Wire Syria en PressRelease 2026-05-04T21:00:00+00:00 Dentsply Sirona Expands U.S. Distribution Footprint Through Enhanced Agreement with Atlanta Dental Supply https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://www.healthwiresyria.com/article/910342356-new-publication-demonstrates-tlx250-px-zircaix-potential-in-diagnosing-kidney-cancers-beyond-ccrcc Health Wire Syria en PressRelease 2026-05-04T21:00:00+00:00 New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.healthwiresyria.com/article/910333422-tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Wire Syria en PressRelease 2026-05-04T20:31:00+00:00 Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d6e37a27-2e33-43bb-ae05-bfb0dedbf190/small/tango-logo-png.png https://www.healthwiresyria.com/article/910333352-teva-to-present-at-the-bofa-securities-health-care-conference Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 Teva to Present at the BofA Securities Health Care Conference https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://www.healthwiresyria.com/article/910333368-vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/dde67700-b1b4-40c4-b930-13bd71804762/small/vor-wordmark-rgb-fullcolor-070920-png.png https://www.healthwiresyria.com/article/910333377-cellectis-to-report-first-quarter-financial-results-on-may-11-2026 Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 Cellectis to Report First Quarter Financial Results on May 11, 2026 https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.healthwiresyria.com/article/910333384-cellectis-publiera-ses-r-sultats-financiers-du-premier-trimestre-le-11-mai-2026 Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026 https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.healthwiresyria.com/article/910333394-olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png https://www.healthwiresyria.com/article/910333396-crispr-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/5dac7d0d-131d-4047-bab7-db8e0719bf58/small/crispr-logo-jpg.jpg https://www.healthwiresyria.com/article/910333417-jushi-holdings-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026 Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 Jushi Holdings Inc. to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/e65f15fd-322c-4847-83c5-ceafe27f97d5/small/jushi-png.png https://www.healthwiresyria.com/article/910333429-opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg https://www.healthwiresyria.com/article/910333432-eton-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026 Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 https://ml.globenewswire.com/media/db07cafa-b35c-4d61-a1a1-d330caf67ad2/small/eton-logo-png.png https://www.healthwiresyria.com/article/910333456-bioage-to-host-r-d-day-focused-on-nlrp3-inhibition-on-may-8-2026 Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 https://ml.globenewswire.com/media/d6df9eb5-87f7-4e2e-b503-8a7d8651428e/small/bioage-dark-logo-white-bg-500x500-png.png https://www.healthwiresyria.com/article/910333491-cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population https://ml.globenewswire.com/media/04c4feba-7841-4ac8-8ca5-6c03be383a0e/small/cvrx-outsmart-the-heart-logo-rgb-blue-png.png https://www.healthwiresyria.com/article/910333578-regional-health-properties-announces-appointment-of-marlie-davis-as-chief-financial-officer Health Wire Syria en PressRelease 2026-05-04T20:30:00+00:00 REGIONAL HEALTH PROPERTIES ANNOUNCES APPOINTMENT OF MARLIE DAVIS AS CHIEF FINANCIAL OFFICER https://ml.globenewswire.com/media/bfd51062-4a60-4cf0-9f2f-a4b109b52e4a/small/logo-jpg.jpg https://www.healthwiresyria.com/article/910333399-anaptys-to-participate-at-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference Health Wire Syria en PressRelease 2026-05-04T20:15:00+00:00 Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference https://ml.globenewswire.com/media/eb223f66-e7e0-4e0a-94e7-a3f7a06b13ab/small/anaptys-logo-png.png https://www.healthwiresyria.com/article/910333460-coopercompanies-appoints-paul-keel-to-its-board-of-directors Health Wire Syria en PressRelease 2026-05-04T20:15:00+00:00 CooperCompanies Appoints Paul Keel to its Board of Directors https://ml.globenewswire.com/media/10a4810f-301c-4d8c-851d-dd09334d10d5/small/coopercompanies-aqua-logo-horz-jpg.jpg https://www.healthwiresyria.com/article/910324477-inspiremd-reports-first-quarter-2026-financial-results Health Wire Syria en PressRelease 2026-05-04T20:05:00+00:00 InspireMD Reports First Quarter 2026 Financial Results https://ml-eu.globenewswire.com/media/5aefda10-5578-41c7-a1c0-9c4b700687c0/small/inspiremd-jpg.jpg https://www.healthwiresyria.com/article/910324487-option-care-health-to-participate-in-the-bank-of-america-health-care-conference Health Wire Syria en PressRelease 2026-05-04T20:05:00+00:00 Option Care Health to Participate in the Bank of America Health Care Conference https://ml.globenewswire.com/media/YWM2YTg3MzEtODAyYy00ZmVkLWE5YzUtNDk2YjA4MDU0ZWIxLTEwMTk5NzQtMjAyNi0wNS0wNC1lbg==/tiny/Option-Care-Health-Inc-.png https://www.healthwiresyria.com/article/910324540-kyntra-bio-to-report-first-quarter-2026-financial-results Health Wire Syria en PressRelease 2026-05-04T20:05:00+00:00 Kyntra Bio to Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/9105c1e9-d9e3-4b68-9fc8-261fed7db250/small/kyntra-bio-r-rgb-png.png https://www.healthwiresyria.com/article/910324650-capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12 Health Wire Syria en PressRelease 2026-05-04T20:05:00+00:00 Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 https://ml.globenewswire.com/media/16ce4387-5b8f-447c-96b8-7c453633f9bf/small/getimage-48-768x274-png.png https://www.healthwiresyria.com/article/910324654-lexicon-pharmaceuticals-announces-100-million-loan-facility-with-hercules-capital Health Wire Syria en PressRelease 2026-05-04T20:05:00+00:00 Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital https://ml.globenewswire.com/media/afcf3b59-ca71-40ed-9226-a0901bf4d13b/small/logo-jpg.jpg https://www.healthwiresyria.com/article/910324720-aktis-oncology-initiates-phase-1b-clinical-trial-for-aky-2519-a-b7-h3-miniprotein-radioconjugate-in-metastatic-castration-resistant-prostate-cancer Health Wire Syria en PressRelease 2026-05-04T20:05:00+00:00 Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://www.healthwiresyria.com/article/910324723-akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Wire Syria en PressRelease 2026-05-04T20:05:00+00:00 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.healthwiresyria.com/article/910324766-oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates Health Wire Syria en PressRelease 2026-05-04T20:05:00+00:00 ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates https://ml.globenewswire.com/media/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb/small/oric-png.png https://www.healthwiresyria.com/article/910324634-inspire-medical-systems-inc-announces-first-quarter-2026-financial-results-and-updates-2026-guidance Health Wire Syria en PressRelease 2026-05-04T20:02:00+00:00 Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance https://ml.globenewswire.com/media/194e83a5-3f7e-4805-88ce-da2e0ab594df/small/inspire-primary-logo-rgb-daylight-002-png.png https://www.healthwiresyria.com/article/910324758-ocugen-announces-private-offering-of-115-million-of-convertible-senior-notes Health Wire Syria en PressRelease 2026-05-04T20:01:51+00:00 Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.healthwiresyria.com/article/910324495-praxis-precision-medicines-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-and-participate-in-upcoming-investor-conference Health Wire Syria en PressRelease 2026-05-04T20:01:00+00:00 Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.healthwiresyria.com/article/910324509-fibrobiologics-reports-preclinical-data-showing-fibroblast-spheroids-may-actively-reprogram-the-burn-wound-environment-to-drive-healing-and-reduce Health Wire Syria en PressRelease 2026-05-04T20:01:00+00:00 FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.healthwiresyria.com/article/910324510-biodesix-announces-first-quarter-2026-results-and-highlights Health Wire Syria en PressRelease 2026-05-04T20:01:00+00:00 Biodesix Announces First Quarter 2026 Results and Highlights https://ml.globenewswire.com/media/b2fd8e3c-ff04-47d9-938d-93c9c961ccc3/small/bdsx-logo-1200x240-png.png https://www.healthwiresyria.com/article/910324629-hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Health Wire Syria en PressRelease 2026-05-04T20:01:00+00:00 Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/M2UyM2ExNWYtYTJjYi00M2RhLTkwZGEtNjZlYTUyMzI4NTI4LTEzMjE4MjEtMjAyNi0wNS0wNC1lbg==/tiny/Hemab-Therapeutics-Inc-.png https://www.healthwiresyria.com/article/910324649-senseonics-announces-closing-of-92-million-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Health Wire Syria en PressRelease 2026-05-04T20:01:00+00:00 Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares  https://ml.globenewswire.com/media/7f64f449-dd5d-4bd1-9504-82adb3846669/small/logo-png.png https://www.healthwiresyria.com/article/910324596-cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive Health Wire Syria en PressRelease 2026-05-04T20:00:00+00:00 Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png https://www.healthwiresyria.com/article/910324676-providence-saint-john-s-health-center-reinforces-its-commitment-to-maternal-and-newborn-care-through-newly-named-maria-shriver-labor-delivery-and Health Wire Syria en PressRelease 2026-05-04T19:42:13+00:00 Providence Saint John’s Health Center Reinforces its Commitment to Maternal and Newborn Care Through Newly Named Maria Shriver Labor, Delivery and Family Wellness Unit https://ml.globenewswire.com/media/7f052405-cf27-4729-904d-589a86a37d33/medium/think-pink-for-women-s-wellness-supporting-providence-saint.jpg https://www.healthwiresyria.com/article/910306648-aegis-treatment-centers-launches-mobile-medication-vehicle-to-expand-access-to-addiction-care-in-pasadena-and-surrounding-areas Health Wire Syria en PressRelease 2026-05-04T18:45:00+00:00 Aegis Treatment Centers Launches Mobile Medication Vehicle to Expand Access to Addiction Care in Pasadena and Surrounding Areas https://ml.globenewswire.com/media/ZTNhY2M2NTAtZDZhMy00MDM4LWJmMjEtYzhiYzkwOGIwMDcyLTEyNzQyMTYtMjAyNi0wNS0wNC1lbg==/tiny/Pinnacle-Treatment-Centers.png https://www.healthwiresyria.com/article/910291496-sync-supplement-claims-evaluated-the-revive-daily-sunlight-loophole-formula-for-healthy-circadian-rhythm-support Health Wire Syria en PressRelease 2026-05-04T17:18:28+00:00 SYNC Supplement Claims Evaluated: The Revive Daily Sunlight Loophole Formula for Healthy Circadian-Rhythm Support https://zingfast.com/wp-content/uploads/2026/05/SYNC-Supplement.jpg https://www.healthwiresyria.com/article/910291435-sace-launches-out-in-the-open-campaign-for-sexual-violence-awareness-month Health Wire Syria en PressRelease 2026-05-04T17:10:11+00:00 SACE Launches “Out in the Open” Campaign for Sexual Violence Awareness Month https://ml.globenewswire.com/media/M2ZhZGI5YjgtZTI2NS00NmY1LTgzYTEtMmFhMTZmNzI3YmM3LTUwMDE2MjA1My0yMDI2LTA1LTA0LWVu/tiny/Sexual-Assault-Center-of-Edmon.png https://www.healthwiresyria.com/article/910291473-eascra-biotech-welcomes-dr-anne-yau-as-life-science-research-scientist Health Wire Syria en PressRelease 2026-05-04T17:04:04+00:00 Eascra Biotech Welcomes Dr. Anne Yau as Life Science Research Scientist https://ml.globenewswire.com/media/1eda41c1-8c5d-43f0-9198-b0a1570f47e6/medium/dr-anne-yau.jpg https://www.healthwiresyria.com/article/910278476-confluent-medical-technologies-announces-nitinol-wire-center-of-excellence Health Wire Syria en PressRelease 2026-05-04T16:00:00+00:00 Confluent Medical Technologies Announces Nitinol Wire Center of Excellence https://ml.globenewswire.com/media/028bf7c1-4bf6-4b3b-8629-3235829b9477/small/confluent-logo-color-png.png https://www.healthwiresyria.com/article/910272567-when-the-heart-can-t-keep-up-what-to-know-about-heart-failure Health Wire Syria en PressRelease 2026-05-04T15:28:08+00:00 When the Heart Can’t Keep Up: What to Know About Heart Failure https://ml.globenewswire.com/Resource/Download/79158b1b-2b4f-4818-8faa-7574106d7290/17877-1.jpg https://www.healthwiresyria.com/article/910272536-timelycare-acquires-alongside-to-expand-continuous-student-support-with-clinician-powered-ai-coaching Health Wire Syria en PressRelease 2026-05-04T15:00:00+00:00 TimelyCare Acquires Alongside to Expand Continuous Student Support with Clinician-Powered AI Coaching https://ml.globenewswire.com/media/51377623-fd82-411b-9c2c-22d85af45622/medium/alongside-by-timelycare.png https://www.healthwiresyria.com/article/910272574-awareness-is-key-3-steps-to-help-recognize-stroke-signs-and-risks-for-better-outcomes Health Wire Syria en PressRelease 2026-05-04T14:59:07+00:00 Awareness is Key: 3 Steps to Help Recognize Stroke Signs and Risks for Better Outcomes https://ml.globenewswire.com/Resource/Download/71a30026-5d47-467d-b6d5-c5bf1d2b31d8/17855-1.jpg https://www.healthwiresyria.com/article/910266581-flyte-increases-capacity-and-launches-hiring-initiative-as-spirit-airlines-shutdown-disrupts-u-s-air-travel Health Wire Syria en PressRelease 2026-05-04T14:30:00+00:00 Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.healthwiresyria.com/article/910266602-chopped-leaf-launches-new-premium-sandwich-lineup-featuring-toasted-ciabatta-creations Health Wire Syria en PressRelease 2026-05-04T14:24:08+00:00 Chopped Leaf Launches New Premium Sandwich Lineup Featuring Toasted Ciabatta Creations https://ml.globenewswire.com/media/ZGY0ZWI1OTEtNGNhNy00ZmFjLThhN2EtODM5YTdmNmVkMDUxLTEyNzIxMjEtMjAyNi0wNS0wNC1lbg==/tiny/The-Chopped-Leaf.png https://www.healthwiresyria.com/article/910262632-mmi-s-symani-surgical-system-treats-first-alzheimer-s-patient-in-groundbreaking-remind-study Health Wire Syria en PressRelease 2026-05-04T14:10:00+00:00 MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study https://ml.globenewswire.com/media/e9325bed-8fcb-4abf-b66e-6f076014b0fb/small/mmi-logo-stacked-tagline-positive-rgb1-png.png https://www.healthwiresyria.com/article/910262611-research-on-new-class-of-treatments-for-ovarian-cancer-receives-725-000-in-funding-from-ovarian-cancer-canada-to-become-clinical-trial-ready Health Wire Syria en PressRelease 2026-05-04T14:00:00+00:00 Research on new class of treatments for ovarian cancer receives $725,000 in funding from Ovarian Cancer Canada to become “clinical trial-ready” https://ml.globenewswire.com/media/YWY2NGZiYWEtODcyZC00Y2I5LThkZGEtYmM5ZjlkYzFkNDMzLTEzMTI5NjUtMjAyNi0wNS0wNC1lbg==/tiny/Ovarian-Cancer-Canada.png https://www.healthwiresyria.com/article/910262626-spring-allergies-hit-lungs-hard-doctor-of-pharmacy-explains-what-actually-helps Health Wire Syria en PressRelease 2026-05-04T14:00:00+00:00 Spring Allergies Hit Lungs Hard: Doctor of Pharmacy Explains What Actually Helps https://ml.globenewswire.com/media/13a92186-d8d0-4494-9e0a-5fc1d2e363ee/small/betterbrand-logo-new-png.png https://www.healthwiresyria.com/article/910262571-xpress-wellness-acquires-wichita-s-mental-health-clinic-midwest-counseling-services Health Wire Syria en PressRelease 2026-05-04T13:57:00+00:00 Xpress Wellness Acquires Wichita’s Mental Health Clinic Midwest Counseling Services https://ml.globenewswire.com/media/3c8097b3-a387-4dd0-8063-4f48aad75699/small/xpress-wellness-logo-png.png https://www.healthwiresyria.com/article/910258243-cdc-host-tt-certification-for-siemens-healthineers-total-testosterone-test-expands-patient-access-to-gold-standard-equivalent-results Health Wire Syria en PressRelease 2026-05-04T13:30:00+00:00 CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results https://ml.globenewswire.com/media/c5f289d1-b23c-41d2-bfe1-0121523d54b6/small/ https://www.healthwiresyria.com/article/910258255-coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026 Health Wire Syria en PressRelease 2026-05-04T13:30:00+00:00 Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 https://ml.globenewswire.com/media/07437af0-8ae3-48cf-952b-18bc6b99ca7c/small/coherus-onc-logo-rgb-150-png.png https://www.healthwiresyria.com/article/910258286-alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw Health Wire Syria en PressRelease 2026-05-04T13:17:21+00:00 Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.healthwiresyria.com/article/910253033-greece-launches-world-s-first-national-wildfire-satellite-system-with-ororatech Health Wire Syria en PressRelease 2026-05-04T13:04:00+00:00 Greece Launches World’s First National Wildfire Satellite System with OroraTech https://ml.globenewswire.com/media/f405d4dd-2633-4e23-8086-bbaa6bf83b25/medium/ororatech-s-hellenic-fire-system.jpg https://www.healthwiresyria.com/article/910253114-aura-biosciences-announces-pricing-of-260-million-public-offering-of-common-stock-and-pre-funded-warrants Health Wire Syria en PressRelease 2026-05-04T13:03:06+00:00 Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.healthwiresyria.com/article/910252862-carnosyn-brands-expands-tribsyn-applications-across-beverage-dairy-and-medical-nutrition Health Wire Syria en PressRelease 2026-05-04T13:00:00+00:00 CarnoSyn® Brands Expands TriBsyn® Applications Across Beverage, Dairy, and Medical Nutrition https://ml.globenewswire.com/media/4b40dd5b-0137-41f8-83de-422e4b4f3196/small/nai-full-logo-green2-0-png.png https://www.healthwiresyria.com/article/910252869-oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-colorectal-cancer Health Wire Syria en PressRelease 2026-05-04T13:00:00+00:00 Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer https://ml.globenewswire.com/media/f0121259-b2be-4290-90a3-0d2c3b243aed/small/oncolytics-biotech-jpg.jpg https://www.healthwiresyria.com/article/910252878-curated-digital-health-works-now-there-s-a-claims-study-to-prove-it Health Wire Syria en PressRelease 2026-05-04T13:00:00+00:00 Curated Digital Health Works; Now There’s a Claims Study to Prove It https://ml.globenewswire.com/media/b8d88974-2aeb-4baa-ad3b-2ab758ed4dd9/small/solera-main-logo-red-png.png https://www.healthwiresyria.com/article/910252958-biomogging-brings-research-backed-rigour-to-looksmaxxing-as-the-discipline-goes-mainstream Health Wire Syria en PressRelease 2026-05-04T13:00:00+00:00 BioMogging Brings Research-Backed Rigour to Looksmaxxing as the Discipline Goes Mainstream https://ml.globenewswire.com/media/70c5dbfa-bae7-4e93-ac79-cd20cb471a59/medium/biomogging-brings-research-backed-rigour-to-looksmaxxing-as.png https://www.healthwiresyria.com/article/910252971-fate-therapeutics-announces-three-presentations-at-the-2026-asgct-annual-meeting-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and Health Wire Syria en PressRelease 2026-05-04T13:00:00+00:00 Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://www.healthwiresyria.com/article/910253043-gyre-therapeutics-completes-acquisition-of-cullgen-to-create-u-s-and-china-based-fully-integrated-biopharmaceutical-company Health Wire Syria en PressRelease 2026-05-04T12:47:47+00:00 Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company https://ml.globenewswire.com/media/24951768-57e9-4d7a-b969-f00258b17136/small/gyre-logo-png.png https://www.healthwiresyria.com/article/910252933-cannabix-technologies-announces-delivery-of-marijuana-breath-test-mbt-to-workplace-drug-and-alcohol-testing-clinic Health Wire Syria en PressRelease 2026-05-04T12:45:00+00:00 Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Workplace Drug and Alcohol Testing Clinic https://ml.globenewswire.com/media/72457dcd-4783-441b-b82d-641591cd1f13/medium/cannabix-technologies-inc.jpg https://www.healthwiresyria.com/article/910253010-polyrizon-announces-u-s-patent-expansion-for-its-intranasal-drug-delivery-platform Health Wire Syria en PressRelease 2026-05-04T12:45:00+00:00 Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform https://ml.globenewswire.com/media/YWIxMzIzNDgtN2UwNy00NTAyLThjZDMtZWMwNGFjZTdmNWJhLTUwMDEyOTIyMy0yMDI2LTA1LTA0LWVu/tiny/Polyrizon-Ltd-.png https://www.healthwiresyria.com/article/910247536-brainway-launches-personalized-anti-procrastination-app-grounded-in-cbt-earns-6-000-user-reviews Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 Brainway Launches Personalized Anti-Procrastination App Grounded in CBT, Earns 6,000+ User Reviews https://ml-eu.globenewswire.com/media/59f7037f-6f10-4f4b-9b8f-6a7b25f61828/medium/brainway-smarter-focus-built-around-you.png https://www.healthwiresyria.com/article/910247553-mapi-pharma-explores-u-s-aseptic-manufacturing-facility-to-support-growing-demand-for-aseptic-and-long-acting-generic-and-innovative-injectables Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables https://ml.globenewswire.com/media/a15e698a-0f26-4d44-bf6a-78b7ae34d25d/small/mapi-pharma-logo-png.png https://www.healthwiresyria.com/article/910247597-abeona-therapeutics-announces-date-of-first-quarter-financial-results Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 Abeona Therapeutics® Announces Date of First Quarter Financial Results https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://www.healthwiresyria.com/article/910247598-sienna-continues-platform-growth Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 Sienna Continues Platform Growth https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.healthwiresyria.com/article/910247606-dentsply-sirona-launches-smart-view-detect-world-s-first-fda-cleared-ai-enabled-diagnostic-aid-for-detecting-teeth-with-periapical-radiolucencies Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 Dentsply Sirona Launches Smart View - Detect, World’s First FDA-Cleared AI-enabled diagnostic aid for detecting teeth with Periapical Radiolucencies in CBCTs https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://www.healthwiresyria.com/article/910247610-fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.healthwiresyria.com/article/910247613-bicara-therapeutics-to-report-first-quarter-2026-financial-results-and-business-updates-on-may-11-2026-at-8-30-am-et Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://www.healthwiresyria.com/article/910247630-fortress-biotech-to-participate-in-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference https://ml.globenewswire.com/media/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95/small/fortressbio1-jpg.jpg https://www.healthwiresyria.com/article/910247674-newgen-provides-update-on-fiscal-year-2025-results-and-strategic-progress Health Wire Syria en PressRelease 2026-05-04T12:30:00+00:00 NewGen Provides Update on Fiscal Year 2025 Results and Strategic Progress https://ml.globenewswire.com/media/ZWQwY2VjNmQtYTdlZi00YTUxLTg3NmItMmI3OWVkMTQ5MGQ4LTEyOTcwMTEtMjAyNi0wNS0wNC1lbg==/tiny/NewGenIvf-Limited.png https://www.healthwiresyria.com/article/910242525-serefin-health-launches-mycaresteps-program-to-support-care-coordination-across-grey-bruce Health Wire Syria en PressRelease 2026-05-04T12:05:00+00:00 Serefin Health Launches MyCareSteps Program to Support Care Coordination Across Grey Bruce https://ml.globenewswire.com/media/NmJiMmQwN2MtYTlmMi00Njc1LTk1N2QtNmZlYzk1MDJkMTc3LTEzMjMwMzktMjAyNi0wNS0wNC1lbg==/tiny/Serefin-Inc.png https://www.healthwiresyria.com/article/910242598-candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in Health Wire Syria en PressRelease 2026-05-04T12:05:00+00:00 Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://www.healthwiresyria.com/article/910242367-proqr-announces-annual-general-meeting-of-shareholders-to-be-held-june-2-2026 Health Wire Syria en PressRelease 2026-05-04T12:00:00+00:00 ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png https://www.healthwiresyria.com/article/910242370-dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial Health Wire Syria en PressRelease 2026-05-04T12:00:00+00:00 Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial https://ml-eu.globenewswire.com/media/7cf77d4a-25b5-4471-a282-0334907cbfbd/small/falk-logo-rgb-jpg.jpg https://www.healthwiresyria.com/article/910242372-dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial Health Wire Syria en PressRelease 2026-05-04T12:00:00+00:00 Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial https://ml-eu.globenewswire.com/media/540f0a78-db35-42ad-9e90-7b81e8ff3ad6/small/renirl-logo-png.png